Caner Saygin to Disease-Free Survival
This is a "connection" page, showing publications Caner Saygin has written about Disease-Free Survival.
Connection Strength
0.437
-
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 12; 95(12):1457-1465.
Score: 0.148
-
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018 01 10; 8(1):4.
Score: 0.123
-
Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol. 2017 Oct; 92(10):989-996.
Score: 0.119
-
Epithelial-Mesenchymal Transition Markers ß-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study. Pathol Oncol Res. 2015 Sep; 21(4):1209-16.
Score: 0.026
-
Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol. 2013 Aug; 139(8):1373-82.
Score: 0.022